Hillstar Bio is a biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases. Their approach selectively targets and depletes pathogenic immune cells while preserving healthy ones, aiming to provide durable relief and improve patient outcomes. The company's innovative methods leverage tailored discovery techniques, distinguishing them from traditional drug development. They are advancing a pipeline of therapies aimed at specific immune cell subsets for various autoimmune disorders.